Samsung Biologics

Samsung Biologics is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, it provides contract development and manufacturing (CDMO) services to the biopharmaceutical industry. Founded in 2011,[2] Samsung Biologics built three manufacturing plants with a capacity of more than 360,000 liters, from 2011 to 2018, making it the world's largest contract-based manufacturer in the biopharmaceutical sector at a single site as of 2018.[3][4] Since 2020, Samsung Biologics has operated a research and development center in San Francisco, California.[5]

Samsung Biologics Co., Ltd.
TypePublic
KRX: 207940
IndustryBiopharmaceuticals
Founded2011 (2011)
Headquarters
Songdo, Incheon
,
South Korea
Area served
Worldwide
Key people
John Rim, President and CEO[1]
Owners
SubsidiariesSamsung Bioepis
Korean name
Hangul
삼성바이오로직스
Revised RomanizationSamseongbaiorojikseu
Websitewww.samsungbiologics.com

In 2012, it established Samsung Bioepis, a biosimilar medicine producer, with Biogen.[6] The company acquired full ownership of Samsung Bioepis in 2022 by purchasing all remaining shares from Biogen for $2.3 billion.[7]

The company has partnered with GlaxoSmithKline for biologics products,[8] UCB on the production of a clinical trial to treat supranuclear palsy,[9] and with Vir Biotechnology and CytoDyn on the manufacturing of monoclonal antibodies during the COVID-19 pandemic.[10][11] In November 2019, Samsung Biologics became the first contract manufacturing organization to obtain ISO 27001 certification.[12] The company also obtained an ISO 22301 certification in May 2020, the first in the Korean biopharma industry.[13] in April 2022, it was announced Samsung Biologics had acquired Samsung Bioepis (from Biogen), as a wholly owned subsidiary for $2.3 billion USD.[14]

References
  1. Samsung Biologics Names John Rim as President and CEO
  2. "Blazing Samsung Biologics trail into new territory". The Korea Herald. 30 January 2020.
  3. "Samsung BioLogics annual sales up 30% on contract research growth". Korea Biomedical Review. 23 January 2020.
  4. "Samsung Biologics to add new contract drug-making plant". The Korea Times. 20 March 2020.
  5. Dan Stanton (16 June 2020). "Samsung Biologics selects San Francisco for first US facility". BioProcess International.
  6. "Samsung BioLogics no longer a holding company of Samsung Bioepis". The Korea Herald. 5 April 2019.
  7. Angus Liu (28 January 2022). "Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headache". Fierce Pharma.
  8. "GlaxoSmithKline hands Samsung Biologics $231M to scale up manufacturing". Fierce Pharma.
  9. "Samsung Biologics to produce clinical supply as UCB advances Ph I immunotherapy study". Outsourcing Pharma.
  10. "VirBio inks $362M Covid-19 contract manufacturing deal with Samsung Biologics". MedCity News. 12 April 2020.
  11. "Virtaps Samsung to produce coronavirus candidate". C&EN.
  12. "Samsung Biologics receives ISO certification". The Investor.
  13. "Samsung Biologics wins int'l standard for biz continuity (ISO22301) for its third plant". Korea IT Times. 20 May 2020.
  14. "Samsung Biologics completes full acquisition of Samsung Bioepis". European Pharmaceutical Manufacturer. 2022-04-25. Retrieved 2022-04-26.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.